CME Group Inc. (NASDAQ: CME) disclosed its financial performance for the fourth quarter and full year of 2023, showcasing strong figures across key metrics.

Full Year 2023 and Fourth Quarter Financial Overview

In the fourth quarter of 2023, CME Group Inc. reported strong financial results, with revenue reaching $1.4 billion and operating income standing at $863 million.

Net income for the quarter amounted to $815 million. Total revenue for the full year 2023 amounted to $5.6 billion, accompanied by operating income of $3.4 billion. Net income for the year stood at $3.2 billion.

"As global investors turned to our deep, liquid markets to manage risk across asset classes, CME Group average daily volume climbed to a record 24.4 million contracts in 2023, generating both record revenue and adjusted earnings," said Terry Duffy, CME's Group Chairman and Chief Executive Officer.

In the fourth quarter of 2023, average daily volume (ADV) increased 17% compared to the same period in 2022. Non-US ADV saw a notable uptick of 28%. Revenue from clearing and transaction fees in the fourth quarter of 2023 amounted to nearly $1.2 billion. Market data revenue for the same period totaled $167 million.

Introducing CME FX Spot+: Bridging Futures and Spot FX Markets

Earlier, CME Group unveiled plans to launch CME FX Spot+ in 2024, a new spot foreign exchange (FX) marketplace connecting spot FX traders with CME's FX futures liquidity pool, as reported by Finance Magnates.

Using a central limit order book, the platform allows access to CME's futures liquidity in over-the-counter (OTC) spot terms and expands FX futures traders' access to OTC FX liquidity.

Leveraging FX Link, which connects OTC spot FX and CME FX futures trading, CME FX Spot+ will be accessible through CME Globex and EBS Market, benefiting EBS' global spot FX customer base. Paul Houston, CME Group's Global Head of FX Products, emphasized the platform's role in enhancing access, transparency, and trading opportunities across spot FX and FX futures markets.